142 related articles for article (PubMed ID: 7543374)
1. Minor histocompatibility antigen-dependent rejection of Pam 212 epidermoid carcinoma by DBA/2 mice.
Chen Z; Knepper JE; Gaspari AA
Cell Immunol; 1995 Aug; 164(1):90-9. PubMed ID: 7543374
[TBL] [Abstract][Full Text] [Related]
2. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms.
Chen Z; Rosten SI; Lord EM; Gaspari AA
Reg Immunol; 1993; 5(5):285-92. PubMed ID: 8148238
[TBL] [Abstract][Full Text] [Related]
3. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
[TBL] [Abstract][Full Text] [Related]
4. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
Apasov SG; Sitkovsky MV
J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
[TBL] [Abstract][Full Text] [Related]
5. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
6. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
7. Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity.
Gordon LB; Nolan SC; Cserr HF; Knopf PM; Harling-Berg CJ
J Immunol; 1997 Sep; 159(5):2399-408. PubMed ID: 9278331
[TBL] [Abstract][Full Text] [Related]
8. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
[TBL] [Abstract][Full Text] [Related]
9. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
[TBL] [Abstract][Full Text] [Related]
10. The role of class II molecules in Mls 1a recognition by CD4+ T cells is independent of the CD4 molecule.
Borrero H; Collazo L; Macphail S
Cell Immunol; 1993 Dec; 152(2):594-604. PubMed ID: 7903065
[TBL] [Abstract][Full Text] [Related]
11. Generation of T cells with differential responses to alloantigens in CD45 exon 6-deficient mice.
Kong YY; Kishihara K; Yoshida H; Mak TW; Nomoto K
J Immunol; 1995 Jun; 154(11):5725-35. PubMed ID: 7751624
[TBL] [Abstract][Full Text] [Related]
12. Genetic analysis of the presentation of minor lymphocyte stimulating determinants. I. Combined importance of MHC and non-MHC influences.
Ryan JJ; Mond JJ; Finkelman FD
J Immunol; 1988 Aug; 141(4):1063-73. PubMed ID: 3135319
[TBL] [Abstract][Full Text] [Related]
13. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
14. Recognition and response to alloantigens in vivo. I. Negative and positive selection of MLR reactivity in murine peripheral blood lymphocytes to major histocompatibility complex and Mls antigens.
Ryan JJ; Ahmed A; Kind PD; Thompson CB; Berning AK; Sell KW
J Immunol; 1984 Aug; 133(2):606-15. PubMed ID: 6234352
[TBL] [Abstract][Full Text] [Related]
15. Bidirectional blockade of CD4 and major histocompatibility complex class II molecules: an effective immunosuppressive treatment in the mouse heart transplantation model.
Ito H; Hamano K; Fukumoto T; Wood KJ; Esato K
J Heart Lung Transplant; 1998 May; 17(5):460-9. PubMed ID: 9628564
[TBL] [Abstract][Full Text] [Related]
16. Intrathymic alloantigen-mediated, tolerant, completely major histocompatibility complex-mismatched mouse hearts are specifically rejected by adoptively transferred anti-class I L(d+)-specific 2C cells.
Otomo N; Motoyama K; Yu S; Shimizu Y; Margenthaler J; Tu F; Flye MW
Surgery; 2000 Aug; 128(2):206-12. PubMed ID: 10922993
[TBL] [Abstract][Full Text] [Related]
17. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
18. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend SE; Su FW; Atherton JM; Allison JP
Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
[TBL] [Abstract][Full Text] [Related]
19. Murine orthotopic corneal transplantation in high-risk eyes. Rejection is dictated primarily by weak rather than strong alloantigens.
Sano Y; Ksander BR; Streilein JW
Invest Ophthalmol Vis Sci; 1997 May; 38(6):1130-8. PubMed ID: 9152232
[TBL] [Abstract][Full Text] [Related]
20. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
Chen PW; Ananthaswamy HN
J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
